Clinical trial · Observational
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP). This registry is opened in France and in Belgium
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | Breast Implant-Associated Anaplastic Large Cell Lymphoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BIA-ALCL | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- BIA-ALCL
- interventionNames
- Other: BIA-ALCL
Primary outcomes (1)
- measure
- Overall response
- timeFrame
- 13 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with an anaplastic large cell lymphoma associated with breast implants Exclusion Criteria: \-
References
Publications (0)
Data not yet available